Consolidation with Brentuximab Vedotin
Phase 2Antibody–drug conjugate
Consolidation with Brentuximab Vedotin is one of 8 small molecule programs targeting Brentuximab Vedotin. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Brentuximab Vedotin
#DrugCompanyPhaseTrials
1Adriamycin
PfizerPhase 3
Beyfortus
BeiGenePhase 3
DTIC-Dome
BayerPhase 3
Rayos
RRoxane Laboratories
Phase 3
Adcetris
PfizerPhase 2
Vepesid
AAvyxa
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Consolidation with Brentuximab Vedotin
GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Brentuximab Vedotin1 trial
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant
Recruiting·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT04378647·150 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details